Previous 10 | Next 10 |
Gainers: Sintx Technologies (NASDAQ: SINT ) +169% . More news on: Sintx Technologies, Inc., Evoke Pharma, Inc., Ideanomics, Inc., Stocks on the move, , Read more ...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
Genetic testing services provider Invitae (NYSE: NVTA ) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx ( RCHR ), which filed a preliminary prospectus about two weeks ago for an IPO, for up to ~$1.4B. More news on: Invitae Corporation, Ar...
SAN FRANCISCO and BOULDER, Colo. , June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under w...
Wall Street is unabashedly loony at the moment. Stocks remind me of Clark Griswold’s famous line in National Lampoon’s Vacation, “This is crazy, this is crazy, this is crazy.” In every previous recession, corporations reduced their leverage to shore up thei...
Progenity ( PROG ) has filed a prospectus for its IPO of ~6.7M common shares at $14 - 16 per share. Gross proceeds should be ~$100M (midpoint). More news on: Progenity, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Healthcare stocks news, IPO News, , ...
Shares of Invitae (NYSE: NVTA) declined over 10% today as stock markets fell on concerns about the pace of an economic recovery. When stock markets plunged in mid-March, they quickly rallied as Wall Street grew more comfortable that the coronavirus pandemic could be contained and at least pa...
SAN FRANCISCO , June 11, 2020 /PRNewswire/ -- New recommendations from a large, multidisciplinary consensus conference published this week in the Journal of Clinical Oncology suggest expanding use of genetic testing to guide treatment for men with prostate cancer, including the...
Quick Take Progenity ( PROG ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is commercializing molecular testing products to maximize the ability to personalize disease treatments. PROG is dealing with the temporary ...
SAN FRANCISCO , May 28, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...